Renalytix AI plc

Renalytix Plc manufactures medical devices and equipment. It offers artificial intelligence for kidney disease. The company was founded by James McCullough on March 15, 2018 and is headquartered in New York, NY.

Earnings data Q1 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK and SALT LAKE CITY, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release first quarter fiscal year 2022 financial results on Tuesday, December 7, 2021, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (EST) / 1:30 p.m. (GMT).

Renalytix to Report First Quarter Fiscal Year 2022 Financial Results on December 7

Nano-X Imaging

Ocular Therapeutix

With valuations under $2 billion at the moment, these stocks have a lot of room to climb.

3 Small-Cap Stocks to Buy Now and Hold for the Long Haul

Leading clinicians discuss enabling long-term kidney health in Veterans with type 2 diabetes and early-stage chronic kidney disease Leading clinicians discuss enabling long-term kidney health in Veterans with type 2 diabetes and early-stage chronic kidney disease

Renalytix Convenes Expert Panel at VA Healthcare Summit

Partnership expands doctor and patient access to advanced prognosis and coordinated care management of early-stage diabetic kidney disease Partnership expands doctor and patient access to advanced prognosis and coordinated care management of early-stage diabetic kidney disease

St. Joseph's Health and Renalytix Partner to Advance Value-Based Kidney Health in New York

Renalytix Plc's (RNLX) CEO James McCullough on Q4 2021 Results - Earnings Call Transcript

LONDON and SALT LAKE CITY, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX), (LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces its results for the twelve months ended 30 June 2021.

Renalytix Reports Full Year Fiscal 2021 Results

Amyris

You can pick up small pieces of these great businesses for next to nothing.

3 Great Stocks You Can Buy With $50 Right Now

LONDON and SALT LAKE CITY, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release fourth quarter and full year fiscal 2021 financial results on Thursday, October 21, 2021, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (EDT) / 1:30 p.m. (BST).

Renalytix to Report Fourth Quarter and Full Year Fiscal 2021 Financial Results on October 21

Jed Fulk Appointed Vice President Sales, Government Accounts Jed Fulk Appointed Vice President Sales, Government Accounts

Renalytix Launching KidneyIntelX in Veterans Health Administration Hospitals

Invitae

SoFi Technologies

Analyst estimates suggest these stocks can deliver eye-popping gains once the rest of the stock market views them in the same light.

3 Growth Stocks Wall Street Thinks Could Rise 50% or More

Targeted testing run rate of 300 diabetic kidney disease patients per week in calendar Q4 2021 Targeted testing run rate of 300 diabetic kidney disease patients per week in calendar Q4 2021

Mount Sinai Initiates System-wide Scale-Up of Renalytix KidneyIntelX™ Enabled Health Care Model

Hims & Hers Health

Inari Medical

All three are rapidly expanding into their own corners of America's $4 trillion per year healthcare sector.

3 High-Growth Healthcare Stocks to Buy in September

NEW YORK and SALT LAKE CITY, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the company will be presenting at the upcoming 2021 Wells Fargo Virtual Healthcare Conference.

Renalytix to Present at the 2021 Wells Fargo Virtual Healthcare Conference

Levangie brings extensive commercial operating experience to Renalytix, served on boards of Exact Sciences, Insulet Corporation and Hologic Levangie brings extensive commercial operating experience to Renalytix, served on boards of Exact Sciences, Insulet Corporation and Hologic

Renalytix Appoints Daniel J. Levangie to its Board of Directors

Redfin

There's a stock on this list analysts think can climb by around 47%, as soon as more investors come around to their way of seeing things.

3 High-Growth Stocks That Could Soar by 30% or Better According to Wall Street

Peer reviewed publication in Journal of Medical Economics supports payer coverage for early-stage risk assessment and care management in the primary care office Peer reviewed publication in Journal of Medical Economics supports payer coverage for early-stage risk assessment and care management in the primary care office

Payer Budget Impact Analysis Projects Significant Savings from KidneyIntelX™ Testing at Primary Care Level

These potential stock rockets are well worth the different risks they present.

3 High-Growth Healthcare Stocks to Buy in August

NEW YORK, July 26, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the company will be presenting at the upcoming 41st Annual Canaccord Genuity Virtual Global Growth Conference.

Renalytix to Present at the 41st Annual Canaccord Genuity Global Growth Conference

EverBank Financial

Fastly

Find out why these niche businesses keep growing by leaps and bounds.

3 High-Growth Stocks Truly Headed for the Moon

Shares of these overlooked gems could make investors very rich once the rest of the market notices their value.

3 Top Life Science Stocks to Buy on Sale Right Now

Renalytix AI plc (RNLX) CEO James McCullough on Q3 2021 Results - Earnings Call Transcript

NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today reported financial results for the quarter and nine months ended March 31, 2021.

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2021

Renalytix AI PLC (LON:RENX) has seen its shares fall back after losses surged in the third quarter. The company, a developer of diagnostic solutions for kidney disease, said the net loss for the three months to the end of March came in at US$8mln, compared to just US$0.7mln for the same period in 2020.

Renalytix AI falls after R&D costs help push it into hefty loss

Announces Change of Auditor to Ernst & Young LLP Announces Change of Auditor to Ernst & Young LLP

Renalytix to Report Financial Results for Fiscal Third Quarter 2021 and Provide Corporate Update

Enabling expertise in sales, population health and value-driven care models Enabling expertise in sales, population health and value-driven care models

News for Renalytix AI plc Stock (RNLX)